Navigation Links
Patients Often Kept in Dark About 'Off-Label' Drug Use: Study

WEDNESDAY, Aug. 8 (HealthDay News) -- Many patients who are being treated with "off-label" drugs are unaware that the medications they have been prescribed by their doctor aren't being used in ways that would meet U.S. Food and Drug Administration approval, research shows.

Off-label drug use is a term used to describe when a medication is prescribed using a dosage, form of dosage, or for a purpose that hasn't yet been approved by the FDA, the researchers explained in the report published online Aug. 6 in the Mayo Clinic Proceedings.

"Since the U.S. Food and Drug Administration does not regulate the practice of medicine, off-label drug use has become very common," study lead author Dr. Christopher Wittich, an internal medicine physician at the Mayo Clinic in Rochester, Minn., said in a clinic news release. "Health care providers and patients should educate themselves about off-label drugs to weigh the risks and benefits before a physician prescribes one or a patient takes one."

A 2006 report revealed that among the most common medications, roughly one in five prescriptions was for an off-label use, the researchers pointed out. For example, some antidepressants are considered a primary treatment for neuropathic pain, although this use is not FDA-approved.

Morphine, as well as many inhaled bronchodilators, antimicrobials, anticonvulsants and proton pump inhibitors are also prescribed for children without being FDA-approved for use in kids. Previous research has shown that about 79 percent of kids were taking at least one off-label medication when they were discharged from a children's hospital, the study authors noted in the release.

Because doctors are not required to disclose the off-label use of a drug, and are also not liable for off-label drug use, patients are commonly not told that they are taking a drug in a way that is not FDA-approved, the researchers pointed out.

Drug makers, however, are not allowed to promote off-label uses of their drugs. Doing so can result in hefty fines, the study authors explained. For example, GlaxoSmithKline recently agreed to pay a record $3 billion to settle a case involving alleged off-label drug-use marketing, and Merck Sharp & Dohme was fined $322 million for allegedly promoting the painkiller Vioxx for an off-label use.

But, Wittich and colleagues noted, drug companies are allowed to respond to questions from health care providers and distribute peer-reviewed publications about off-label drug use.

The high costs and lengthy process of obtaining FDA approval may deter drug companies from seeking approval for a new drug indication, the researchers suggested.

More information

The American Cancer Society has more about off-label drug use.

-- Mary Elizabeth Dallas

SOURCE: Mayo Clinic, news release, Aug. 6, 2012

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Underinsured Heart Disease Patients Die Sooner, Study Finds
2. Doctors often dont disclose all possible risks to patients before treatment
3. Patients want more risks disclosed before treatment
4. No difference in death rates among patients exposed to common rheumatoid arthritis drugs
5. Weekends More Fatal for Older Patients With Head Injury: Study
6. Coach could be key in helping stroke patients
7. Minority Patients at Higher Risk of Having Ambulances Diverted
8. Tourette Patients Benefit From Behavioral Therapy: Study
9. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
10. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
11. Trauma Patients at Higher Risk of Dying of Hypothermia: Study
Post Your Comments:
Related Image:
Patients Often Kept in Dark About 'Off-Label' Drug Use: Study
(Date:11/30/2015)... ... November 30, 2015 , ... Olympic Gold Medalists ... collaborating with brands across various categories through traditional and social media marketing campaigns ... elite group of Gold Medal Moms who can connect with today’s most important ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. ... the nation’s leading networking organization exclusively for professional women, boasting 850,000 members and ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... programs of the19th Bi-National Convention of the Federation of Philippine American Chambers of ... in Las Vegas, Nevada. , 1Heart Caregiver Services, as an active delegate ...
(Date:11/30/2015)... ... 2015 , ... Until now, the St. Louis Fetal Care Institute ... Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. According ... 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is obese. ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase awareness of ... Your Mouth?” campaign to inform dentists that the technicians they trust could lack ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... RATON, Fla. , Nov. 30, 2015   ... (the Institute) announced today that it has finalized ... device start-up company with technology developed at Florida State ... publicly-funded research, and bridges early funding gaps for companies ... and research institutions. --> ...
(Date:11/30/2015)... Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 ... 384,242 , 9.8 Hospital Management Service Income ... (18.3) Medical Insurance Administration Service Income , 2,780 ... Accessories Sales , 89,645 , 94,580 ... , 2,917 , (3.3) Gross Profit ...
(Date:11/30/2015)... -- PTS Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing ... systems, and PTS Detect™ cotinine systems, has announced ... propel the company into the mHealth market. ... . The technology is a system that interfaces with ... tablets, and uses test strip technology already developed by ...
Breaking Medicine Technology: